Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors.

Investigational new drugs - 1 Oct 2011

Sanoff Hanna K, Davies Janine M, Walko Christine, Irvin William, Buie Larry, Keller Kimberly, Ivanova Anastasia, Chiu Wing-Keung, O'Neil Bert H, Stinchcombe Thomas E, Dees E Claire

Abstract excerpt

PURPOSE: Epidermal growth factor receptor (EGFR) inhibition may overcome chemotherapy resistance by inhibiting important anti-apoptotic signals that are constitutively activated by an overstimulated EGFR pathway. METHODS: This phase I dose escalation trial assessed the safety and efficacy of vinflunine, a novel vinca alkaloid microtubule inhibitor, with erlotinib, an EGFR tyrosine kinase inhibitor, in patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP3A

Share to Dose-Response Relationship, Drug

Share to Drug Resistance, Neoplasm

Share to Erlotinib Hydrochloride

Share to Quinazolines

Share to Vinblastine

Source

Open in PubMed Open full text

Identifiers

PMID: 20387090
DOI: 10.1007/s10637-010-9427-1
PMCID: PMC2988886

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors.PMID 20387090Read ↗

Phase I trial of vinflunine and pemetrexed in refractory solid tumors.Semantic proximity Read ↗

Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenograftsSemantic proximity Read ↗

Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.Semantic proximity Read ↗

Phase Ia/Ib trial of the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M).Semantic proximity Read ↗

Metronomic oral vinorelbine doublet chemotherapy with carboplatin in treatment of advanced lung cancer: a feasibility and safety studySemantic proximity Read ↗

A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors.Semantic proximity Read ↗

Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.Semantic proximity Read ↗

Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors.Semantic proximity Read ↗

Antitumor effects of erlotinib in combination with berberine in A431 cells.Semantic proximity Read ↗

Intermittent chemotherapy and erlotinib for nonsmokers or light smokers with advanced adenocarcinoma of the lung: a phase II clinical trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.